company background image
LADX

LadRx OTCPK:LADX Stock Report

Last Price

US$0.18

Market Cap

US$8.1m

7D

-2.4%

1Y

-69.9%

Updated

27 Nov, 2022

Data

Company Financials
LADX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

LADX Stock Overview

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer.

LadRx Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LadRx
Historical stock prices
Current Share PriceUS$0.18
52 Week HighUS$0.69
52 Week LowUS$0.052
Beta2.12
1 Month Change9.39%
3 Month Change125.63%
1 Year Change-69.91%
3 Year Change-37.76%
5 Year Change-91.41%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Shareholder Returns

LADXUS BiotechsUS Market
7D-2.4%0.4%1.3%
1Y-69.9%-14.4%-18.5%

Return vs Industry: LADX underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: LADX underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is LADX's price volatile compared to industry and market?
LADX volatility
LADX Average Weekly Movement23.4%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: LADX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: LADX's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19853Stephen Snowdyhttps://www.cytrx.com

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company’s advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022.

LadRx Corporation Fundamentals Summary

How do LadRx's earnings and revenue compare to its market cap?
LADX fundamental statistics
Market CapUS$8.13m
Earnings (TTM)-US$12.95m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LADX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$12.95m
Earnings-US$12.95m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.29
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LADX perform over the long term?

See historical performance and comparison